These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas. Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170 [TBL] [Abstract][Full Text] [Related]
6. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565 [TBL] [Abstract][Full Text] [Related]
7. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis. Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314 [TBL] [Abstract][Full Text] [Related]
8. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871 [TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829 [TBL] [Abstract][Full Text] [Related]
10. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478 [TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508 [TBL] [Abstract][Full Text] [Related]
12. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579 [TBL] [Abstract][Full Text] [Related]
13. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Nagamatsu A; Umesaki N; Li L; Tanaka T Oncol Rep; 2010 Apr; 23(4):1069-76. PubMed ID: 20204293 [TBL] [Abstract][Full Text] [Related]
14. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008 [TBL] [Abstract][Full Text] [Related]
15. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255 [TBL] [Abstract][Full Text] [Related]
16. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531 [TBL] [Abstract][Full Text] [Related]
17. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Hasegawa T Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):683-91. PubMed ID: 16506050 [TBL] [Abstract][Full Text] [Related]
18. Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. Strauss LG; Dimitrakopoulou-Strauss A; Haberkorn U J Nucl Med; 2003 Dec; 44(12):1933-9. PubMed ID: 14660719 [TBL] [Abstract][Full Text] [Related]
19. Role of PET/PET-CT in the management of sarcomas. Kumar R; Chauhan A; Vellimana AK; Chawla M Expert Rev Anticancer Ther; 2006 Aug; 6(8):1241-50. PubMed ID: 16925490 [TBL] [Abstract][Full Text] [Related]
20. Short dynamic FDG-PET imaging protocol for patients with lung cancer. Torizuka T; Nobezawa S; Momiki S; Kasamatsu N; Kanno T; Yoshikawa E; Futatsubashi M; Okada H; Ouchi Y Eur J Nucl Med; 2000 Oct; 27(10):1538-42. PubMed ID: 11083544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]